Open AccessCost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
Author(s) -
William V. Padula,
Richard A. Larson,
Stacie B. Dusetzina,
Jane F. Apperley,
Rüdiger Hehlmann,
Michele Baccarani,
Ekkehard Eigendorff,
Joëlle Guilhot,
François Guilhot,
FrançoisXavier Mahon,
Giovanni Martinelli,
Jiřı́ Mayer,
Martin Müller,
Dietger Niederwieser,
Susanne Saußele,
Charles A. Schiffer,
Richard T. Silver,
Bengt Simonsson,
Rena M. Conti
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/h6kv-p452
Subject(s) - imatinib , myeloid leukemia , tyrosine kinase inhibitor , tyrosine kinase , medicine , cancer research , pharmacology , receptor , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom